Logo

Sentigen Shareholders Approve Invitrogen Acquisition

Nov 15, 2006
NEW YORK (GenomeWeb News) - Sentigen Holding today said that its stockholders have approved its planned merger with Invitrogen.
 
Sentigen said it expects the deal to close “within the next several weeks.”
 
As GenomeWeb News reported in August, Invitrogen said it planned to acquire Sentigen, which includes its subsidiaries Sentigen Biosciences and Cell & Molecular Technologies for
For around $25.9 million.

Breaking News
The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.